Recent events
Recent events tied to this brand in public sources.
Back to profile27 entries · Page 1 of 2
2026
Gilead announces acquisition of PepStar oral inflammation drug program
Gilead said it would acquire PepStar Therapeutics’ oral inflammation drug program for a $1.275 billion cash upfront payment. The program includes an experimental treatment for intestinal disease.
2021
Royalty Pharma sues Gilead over royalties
Royalty Pharma Collection Trust sued Gilead Sciences over alleged failure to pay royalties for use of a patent covering emtricitabine. The plaintiffs allege that Gilead used the patented treatment in more than ten drug combinations and breached a royalty-payment contract; these are allegations, not findings stated in the source.
2021
Patients sue Gilead over alleged toxicity and disclosure of HIV drug risks
Patients with HIV brought a civil suit against Gilead, accusing the company of failing to properly report potential health effects of its HIV drugs and alleging that the drugs caused kidney and bone problems. The claims are allegations by the plaintiffs, not a court determination.
2021
Gilead supports expanded local remdesivir production in India
Gilead said it was providing its voluntary licensing partners with technical assistance, support for adding local manufacturing facilities, and donated active pharmaceutical ingredient to scale up remdesivir production in India.
2021
Gilead sues Russia over remdesivir compulsory license
Gilead Sciences filed a lawsuit against the Russian government over its authorization for a domestic company to manufacture and market remdesivir, also known as Veklury. The article says the government had issued a compulsory license to Pharmasyntez.
2021
Gilead Sciences announces Bill Lee's retirement
Gilead Sciences announced that Bill Lee, PhD, was retiring from the company after three decades. The source does not state the retirement date.
2021
Gilead Sciences announces Flavius Martin as research executive vice president
Gilead Sciences announced that Flavius Martin would join the company as executive vice president of research and join its senior leadership team, assuming responsibility for the research organization effective April 12, 2021.
2021
Gilead completes acquisition of MYR GmbH
Gilead Sciences announced completion of its acquisition of MYR GmbH for up to approximately €1.45 billion in aggregate cash consideration. MYR became a wholly owned subsidiary of Gilead.
2020
Gilead announces acquisition of MYR
Gilead announced an all-cash deal to acquire German biopharmaceutical company MYR for 1.15 billion euros. The transaction was expected to close in the first quarter of the following year; completion had not yet occurred in the report.
2020
Gilead launches Racial Equity Community Impact Fund
Gilead announced the launch of a fund that will initially provide $10 million in grants to 20 organizations over three years to support organizations working to address racial inequities affecting Black communities in the United States.
2020
ProteoNic licenses 2G UNic technology to Gilead Sciences
ProteoNic announced that it licensed its 2G UNic technology to Gilead Sciences. The agreement grants Gilead non-exclusive commercial rights to apply the platform to development of its proprietary products from mammalian cells.
2020
Gilead completes acquisition of Immunomedics
Gilead completed its acquisition of Immunomedics for approximately $21 billion. Immunomedics became a wholly owned subsidiary of Gilead, and its common stock was to cease trading on Nasdaq.
2020
FDA approves Veklury for COVID-19 treatment
The U.S. Food and Drug Administration approved Gilead Sciences' antiviral drug remdesivir, sold under the brand name Veklury, as a treatment for COVID-19 patients requiring hospitalization.
2020
Gilead announced its acquisition of Immunomedics
Gilead announced it would acquire biotechnology company Immunomedics for $21 billion, with the deal expected to close in the fourth quarter of 2020.
2020
Gilead and Tango expand cancer-therapy collaboration
Gilead Sciences and Tango Therapeutics announced an expansion of their existing collaboration focused on discovering, developing and commercializing targeted immune-evasion therapies for cancer.
2020
Gilead raises 2020 sales forecast
Gilead Sciences raised its 2020 sales forecast to $23 billion–$25 billion from its previous range of $21.8 billion–$22.2 billion, including expected remdesivir revenue.
2020
Gilead begins commercial sales of remdesivir
Gilead began commercial sales of remdesivir, an antiviral drug administered by infusion to hospitalized patients.
2020
Gilead and Arcus sign oncology collaboration deal
Gilead Sciences signed a 10-year collaboration deal with Arcus Biosciences to co-develop and co-commercialise current and future cancer therapeutic candidates in Arcus's pipeline. The deal is valued at up to $1.97 billion.
2020
Cipla signs non-exclusive Remdesivir license with Gilead Sciences
Cipla signed a non-exclusive licensing agreement with Gilead Sciences to manufacture and distribute Remdesivir. The agreement permits Cipla to manufacture the active pharmaceutical ingredient and finished product and market them in 127 countries, including India and South Africa.
2020
Gilead completes acquisition of Forty Seven
Gilead announced completion of the acquisition of Forty Seven by a Gilead subsidiary. Forty Seven became a wholly owned subsidiary of Gilead, and its common stock would no longer be listed for trading on the Nasdaq Global Select Market.